LNP 023

Next Previous
Drug Profile

LNP 023

Alternative Names: LNP023

Latest Information Update: 18 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Anti-inflammatories
  • Mechanism of Action Complement-Factor-B-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Paroxysmal nocturnal haemoglobinuria
  • Phase I IgA nephropathy

Most Recent Events

  • 11 Apr 2018 Phase-II clinical trials in Paroxysmal nocturnal haemoglobinuria in Italy, Germany (PO) (NCT03439839)
  • 26 Feb 2018 Novartis plans a phase II trial for Paroxysmal nocturnal haemoglobinuria, in February 2018 (NCT03439839) (EudraCT2017-000888-33)
  • 27 Dec 2017 Novartis Pharmaceuticals plans a phase II trial for IgA Nephropathy in December 2017 (NCT03373461)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top